Transparency in decision modelling: what, why, who, and how?

التفاصيل البيبلوغرافية
العنوان: Transparency in decision modelling: what, why, who, and how?
المؤلفون: Philip Clarke, Edward C. F. Wilson, Deborah A. Marshall, Neil Hawkins, Tim Wrightson, Stirling Bryan, Mohsen Sadatsafavi, Sean Ekins, Anthony J. Hatswell, Renée J.G. Arnold, Will Sullivan, Sue Langham, Christopher Sampson
المصدر: Pharmacoeconomics
سنة النشر: 2019
مصطلحات موضوعية: Technology Assessment, Biomedical, Decision Making, Stakeholder engagement, Principle of legality, Intellectual property, Article, Decision Support Techniques, 03 medical and health sciences, 0302 clinical medicine, Data Protection Act 1998, Humans, 030212 general & internal medicine, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries), Pharmacology, business.industry, 030503 health policy & services, Health Policy, Public Health, Environmental and Occupational Health, Health technology, Public relations, Transparency (behavior), Intellectual Property, Incentive, Software deployment, Business, 0305 other medical science, Software
الوصف: Transparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experience. We outline a taxonomy of the different manifestations of transparency, including reporting standards, reference models, collaboration, model registration, peer review, and open source modelling. Further, we map out the role and incentives for the various stakeholders, including industry, research organisations, publishers, and decision-makers. We outline the anticipated advantages and disadvantages of greater transparency with respect to each manifestation, as well as the perceived barriers and facilitators to greater transparency. These are considered with respect to the different stakeholders and with reference to issues including intellectual property, legality, standards, quality assurance, code integrity, health technology assessment processes, incentives, funding, software, access and deployment options, data protection, and stakeholder engagement. For each manifestation of transparency, we discuss the ‘what’, ‘why’, ‘who’, and ‘how’. Specifically, their meaning, why the community might (or might not) wish to embrace them, whose engagement as stakeholders is required, and how relevant objectives might be realised. We identify current initiatives aimed to improve transparency to exemplify efforts in current practice and for the future.
وصف الملف: application/pdf
اللغة: English
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ba7a62ea96b8a6acd78c9e941ee54e
https://europepmc.org/articles/PMC8237575/
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....01ba7a62ea96b8a6acd78c9e941ee54e
قاعدة البيانات: OpenAIRE